Cargando…

Enhanced Lipid Peroxidation and Platelet Activation as Potential Contributors to Increased Cardiovascular Risk in the Low‐HDL Phenotype

BACKGROUND: Low high‐density lipoprotein (HDL) levels are major predictors of cardiovascular (CV) events, even in patients on statin treatment with low‐density lipoprotein (LDL) at target. In animal models HDLs protect LDL from oxidation and blunt platelet activation. Our study aimed to examine whet...

Descripción completa

Detalles Bibliográficos
Autores principales: Vazzana, Natale, Ganci, Antonina, Cefalù, Angelo Baldassare, Lattanzio, Stefano, Noto, Davide, Santoro, Nicole, Saggini, Raoul, Puccetti, Luca, Averna, Maurizio, Davì, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3647282/
https://www.ncbi.nlm.nih.gov/pubmed/23557750
http://dx.doi.org/10.1161/JAHA.113.000063
_version_ 1782268709457362944
author Vazzana, Natale
Ganci, Antonina
Cefalù, Angelo Baldassare
Lattanzio, Stefano
Noto, Davide
Santoro, Nicole
Saggini, Raoul
Puccetti, Luca
Averna, Maurizio
Davì, Giovanni
author_facet Vazzana, Natale
Ganci, Antonina
Cefalù, Angelo Baldassare
Lattanzio, Stefano
Noto, Davide
Santoro, Nicole
Saggini, Raoul
Puccetti, Luca
Averna, Maurizio
Davì, Giovanni
author_sort Vazzana, Natale
collection PubMed
description BACKGROUND: Low high‐density lipoprotein (HDL) levels are major predictors of cardiovascular (CV) events, even in patients on statin treatment with low‐density lipoprotein (LDL) at target. In animal models HDLs protect LDL from oxidation and blunt platelet activation. Our study aimed to examine whether HDL levels are related to in vivo oxidative stress and platelet activation, as determinants of atherothrombosis. METHODS AND RESULTS: Urinary 8‐iso‐PGF(2α) and 11‐dehydro‐TXB(2), in vivo markers of oxidative stress and platelet activation, respectively, were measured in 65 coronary heart disease (CHD) normocholesterolemic patients with HDL ≤35 mg/dL, and in 47 CHD patients with HDL >35 mg/dL. The 2 eicosanoids were also measured before and after an intensive exercise program in sedentary people (n=18) and before and after fenofibrate treatment in otherwise healthy subjects with low HDL (n=10). Patients with HDL ≤35 mg/dL showed significantly higher urinary 8‐iso‐PGF(2α) (median [25th to 75th percentiles]: 289 [189 to 380] versus 216 [171 to 321] pg/mg creatinine, P=0.019) and 11‐dehydro‐TXB(2) (563 [421 to 767] versus 372 [249 to 465] pg/mg creatinine, P=0.0001) than patients with higher HDL. A direct correlation was found between urinary 8‐iso‐PGF(2α) and 11‐dehydro‐TXB(2) in the entire group of patients (ρ=0.77, P<0.0001). HDL levels were inversely related to both 8‐iso‐PGF(2α) (ρ=−0.32, P=0.001) and 11‐dehydro‐TXB(2) (ρ=−0.52, P<0.0001). On multiple regression, only 8‐iso‐PGF(2α) (β=0.68, P<0.0001) and HDL level (β=−0.29, P<0.0001) were associated with urinary 11‐dehydro‐TXB(2) excretion, independent of sex, age, smoking, hypertension, diabetes, previous myocardial infarction, total cholesterol, LDL, and triglycerides. Both intensive exercise and fenofibrate treatment significantly reduced the 2 eicosanoids in healthy subjects, in parallel with an HDL increase. CONCLUSIONS: A low HDL phenotype, both in CHD patients and in healthy subjects, is associated with increased lipid peroxidation and platelet activation. These data provide novel insight into the mechanisms linking low HDL with increased CV risk.
format Online
Article
Text
id pubmed-3647282
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-36472822013-05-08 Enhanced Lipid Peroxidation and Platelet Activation as Potential Contributors to Increased Cardiovascular Risk in the Low‐HDL Phenotype Vazzana, Natale Ganci, Antonina Cefalù, Angelo Baldassare Lattanzio, Stefano Noto, Davide Santoro, Nicole Saggini, Raoul Puccetti, Luca Averna, Maurizio Davì, Giovanni J Am Heart Assoc Original Research BACKGROUND: Low high‐density lipoprotein (HDL) levels are major predictors of cardiovascular (CV) events, even in patients on statin treatment with low‐density lipoprotein (LDL) at target. In animal models HDLs protect LDL from oxidation and blunt platelet activation. Our study aimed to examine whether HDL levels are related to in vivo oxidative stress and platelet activation, as determinants of atherothrombosis. METHODS AND RESULTS: Urinary 8‐iso‐PGF(2α) and 11‐dehydro‐TXB(2), in vivo markers of oxidative stress and platelet activation, respectively, were measured in 65 coronary heart disease (CHD) normocholesterolemic patients with HDL ≤35 mg/dL, and in 47 CHD patients with HDL >35 mg/dL. The 2 eicosanoids were also measured before and after an intensive exercise program in sedentary people (n=18) and before and after fenofibrate treatment in otherwise healthy subjects with low HDL (n=10). Patients with HDL ≤35 mg/dL showed significantly higher urinary 8‐iso‐PGF(2α) (median [25th to 75th percentiles]: 289 [189 to 380] versus 216 [171 to 321] pg/mg creatinine, P=0.019) and 11‐dehydro‐TXB(2) (563 [421 to 767] versus 372 [249 to 465] pg/mg creatinine, P=0.0001) than patients with higher HDL. A direct correlation was found between urinary 8‐iso‐PGF(2α) and 11‐dehydro‐TXB(2) in the entire group of patients (ρ=0.77, P<0.0001). HDL levels were inversely related to both 8‐iso‐PGF(2α) (ρ=−0.32, P=0.001) and 11‐dehydro‐TXB(2) (ρ=−0.52, P<0.0001). On multiple regression, only 8‐iso‐PGF(2α) (β=0.68, P<0.0001) and HDL level (β=−0.29, P<0.0001) were associated with urinary 11‐dehydro‐TXB(2) excretion, independent of sex, age, smoking, hypertension, diabetes, previous myocardial infarction, total cholesterol, LDL, and triglycerides. Both intensive exercise and fenofibrate treatment significantly reduced the 2 eicosanoids in healthy subjects, in parallel with an HDL increase. CONCLUSIONS: A low HDL phenotype, both in CHD patients and in healthy subjects, is associated with increased lipid peroxidation and platelet activation. These data provide novel insight into the mechanisms linking low HDL with increased CV risk. Blackwell Publishing Ltd 2013-04-24 /pmc/articles/PMC3647282/ /pubmed/23557750 http://dx.doi.org/10.1161/JAHA.113.000063 Text en © 2013 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley-Blackwell. http://creativecommons.org/licenses/by/2.5/ This is an Open Access article under the terms of the Creative Commons Attribution Noncommercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Research
Vazzana, Natale
Ganci, Antonina
Cefalù, Angelo Baldassare
Lattanzio, Stefano
Noto, Davide
Santoro, Nicole
Saggini, Raoul
Puccetti, Luca
Averna, Maurizio
Davì, Giovanni
Enhanced Lipid Peroxidation and Platelet Activation as Potential Contributors to Increased Cardiovascular Risk in the Low‐HDL Phenotype
title Enhanced Lipid Peroxidation and Platelet Activation as Potential Contributors to Increased Cardiovascular Risk in the Low‐HDL Phenotype
title_full Enhanced Lipid Peroxidation and Platelet Activation as Potential Contributors to Increased Cardiovascular Risk in the Low‐HDL Phenotype
title_fullStr Enhanced Lipid Peroxidation and Platelet Activation as Potential Contributors to Increased Cardiovascular Risk in the Low‐HDL Phenotype
title_full_unstemmed Enhanced Lipid Peroxidation and Platelet Activation as Potential Contributors to Increased Cardiovascular Risk in the Low‐HDL Phenotype
title_short Enhanced Lipid Peroxidation and Platelet Activation as Potential Contributors to Increased Cardiovascular Risk in the Low‐HDL Phenotype
title_sort enhanced lipid peroxidation and platelet activation as potential contributors to increased cardiovascular risk in the low‐hdl phenotype
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3647282/
https://www.ncbi.nlm.nih.gov/pubmed/23557750
http://dx.doi.org/10.1161/JAHA.113.000063
work_keys_str_mv AT vazzananatale enhancedlipidperoxidationandplateletactivationaspotentialcontributorstoincreasedcardiovascularriskinthelowhdlphenotype
AT ganciantonina enhancedlipidperoxidationandplateletactivationaspotentialcontributorstoincreasedcardiovascularriskinthelowhdlphenotype
AT cefaluangelobaldassare enhancedlipidperoxidationandplateletactivationaspotentialcontributorstoincreasedcardiovascularriskinthelowhdlphenotype
AT lattanziostefano enhancedlipidperoxidationandplateletactivationaspotentialcontributorstoincreasedcardiovascularriskinthelowhdlphenotype
AT notodavide enhancedlipidperoxidationandplateletactivationaspotentialcontributorstoincreasedcardiovascularriskinthelowhdlphenotype
AT santoronicole enhancedlipidperoxidationandplateletactivationaspotentialcontributorstoincreasedcardiovascularriskinthelowhdlphenotype
AT sagginiraoul enhancedlipidperoxidationandplateletactivationaspotentialcontributorstoincreasedcardiovascularriskinthelowhdlphenotype
AT puccettiluca enhancedlipidperoxidationandplateletactivationaspotentialcontributorstoincreasedcardiovascularriskinthelowhdlphenotype
AT avernamaurizio enhancedlipidperoxidationandplateletactivationaspotentialcontributorstoincreasedcardiovascularriskinthelowhdlphenotype
AT davigiovanni enhancedlipidperoxidationandplateletactivationaspotentialcontributorstoincreasedcardiovascularriskinthelowhdlphenotype